Intralesional Rituximab for Idiopathic Dacryoadenitis

In this interview, Drs. Julian Perry and Catherine Hwang discuss the use of intralesional rituximab to treat idiopathic dacryoadenitis. Outcomes from a 7-year study indicate that 19 patients who received rituximab showed resolution after 4 weeks of treatment. Orbital inflammation scores declined significantly. Two patients relapsed, but repeat treatment led to resolution. 

Relevant Financial Disclosures: None